Additionally, Park et al. reported on overall ORR of 83% and median brain radiotherapy-free interval of 12.6 months (95% CI, 7.6–17.6) with gefitinib and erlotinib in patients with EGFR-mutant NSCLC and brain metastases, whereas 15 patients enrolled in the study (54% of the study population) had some neurological symptoms at baseline [34]. Here, EGFR is linked to non-small cell lung carcinoma.